Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

5 results about "Dihydropyrimidinuria" patented technology

A number sign (#) is used with this entry because of evidence that dihydropyrimidinase deficiency is caused by homozygous or compound heterozygous mutation in the DPYS gene ... DPYS deficiency is an autosomal recessive disease characterized by the presence of dihydropyrimidinuria. The clinical phenotype is highly variable, ranging from early ...

Dihydropyrimidine compound, preparation method therefor and use thereof

PendingEP4410785A4improved P2X3 receptor antagonismimprove securityOrganic active ingredientsOrganic chemistryBiochemical engineeringDihydropyrimidinuria
Disclosed are a dihydropyrimidine based compound, a preparation method therefor and an application thereof, belonging to the technical field of pharmaceutical chemistry. The present invention relates to a dihydropyrimidine based compound, the structure of which is shown in formula I. Also provided in the present invention is an application of the compound represented by formula I, or a salt, solvate, isomer, metabolite, nitrogen oxide and prodrug thereof, in the preparation of a medicament for treating or preventing P2X3 and / or P2X2 / 3 receptor-related diseases. The dihydropyrimidine based compound of the present invention has good P2X3 receptor antagonist activity and improved safety.
Owner:CHENGDU SHIBEIKANG BIOLOGICAL MEDICINE TECH CO LTD

2,3-dihydropyrimido[4,5-d]pyrimidin-4(1h)-one derivatives, processes for their preparation and uses thereof

The application belongs to the technical field of chemical medicine, and particularly relates to a kind of 2,3-dihydropyrimidino [4,5-d] pyrimidine-4 (1H) -ketone derivatives and preparation method and purposes thereof.The existing Wee1 small molecule inhibitors still have one or more defects in activity, safety or pharmacokinetic properties, and a new generation of Wee1 small molecule inhibitors with novel structure, low toxicity, high efficiency and excellent pharmacokinetic properties needs to be developed.The application provides a kind of 2,3-dihydropyrimidino [4,5-d] pyrimidine-4 (1H) -ketone derivatives, specifically including 95 new compounds, or pharmaceutically acceptable salt thereof, or stereoisomer thereof.Experiments show that the compound of formula (I) disclosed in the application has good inhibitory activity on Wee1, and therefore the compound of the application can be used for treating diseases caused by abnormal Wee1 activity.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV

Dihydropyrimidine[4,5-d]pyrimidine-2(h)-one nrf2 activators and methods of making and using the same

ActiveCN117384167BOrganic active ingredientsNervous disorderDihydropyrimidinuriaKetone
The application discloses a dihydropyrimidine[4,5-d]pyrimidine-2(H)-ketone Nrf2 activator and a preparation method and application thereof. The compound has the following structural general formula: experiments prove that the compound can effectively activate the Nrf2 signal pathway to produce an antioxidative stress effect, thereby protecting nerve cells, and can be used for preventing and / or treating neurodegenerative diseases.
Owner:CAMBRIAN ZHIYUAN (NANJING) BIOMEDICAL TECH CO LTD